Letters to HCPs
Important information for Healthcare Professionals
Febuxostat (ADENURIC): Increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study
Summary: In a phase IV clinical study (the CARES study) in patients with gout and a history of major CV disease, a significant higher risk of all-cause mortality and for CV-related death was observed in patients treated with febuxostat compared to those treated with allopurinol. Treatment with febuxostat in patients with pre-existing major CV disease should be avoided, unless no other therapy options are appropriate.
For Healthcare Professionals